Stem Cell Clinic

Promethera Announces Initiation of Phase 2b DHELIVER Study of HepaStem in Patients with Acute-on-Chronic Liver Failure (ACLF) – Business Wire

MONT-SAINT-GUIBERT, Belgium & TOKYO--(BUSINESS WIRE)--Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the initiation of a Phase 2b clinical trial to evaluate the efficacy and safety of HepaStem, the companys liver-derived stem cell therapy candidate, in patients with Acute-on-Chronic Liver Failure (ACLF). The trial is open for recruitment and aims to include 363 patients with ACLF at 110 study sites across 22 countries in Europe. Topline results are expected to be released at a medical conference at the end of 2023.

The DHELIVER study (or HEP102) is a randomized, placebo-controlled, double-blinded, multicenter trial designed to assess the efficacy of HepaStem treatment on the overall survival proportion 90 days post-first infusion. Among the secondary trial objectives are additional efficacy assessments such as transplantation-free survival as well as continued evaluation of the treatments safety. Patients with Grade 1 or 2 ACLF will be eligible to screen for participation in the trial. The study will target enrolment of approximately 363 patients across two treatment arms: patients receiving two weekly intravenous infusions of HepaStem and patients receiving placebo.

We are developing HepaStem as a treatment for ACLF at a fast pace and we are determined to bring it to patients in need as soon as we can. As a potentially pivotal trial, the results obtained here may provide us with sufficient clinical data to file a new drug application, said Etienne Sokal, M.D., Ph.D., Founder and Group Chief Medical Officer of Promethera. Providing a treatment for a severe disease such as ACLF will not only help this patient population, but also greatly inform us in our efforts to develop treatments for other liver diseases, such as NASH.

ACLF is a severe, life threatening disease, with no current available treatments. The only option for patients is organ transplant, which is a major procedure and often not accessible. HepaStem has the potential to be the first real alternative to liver transplants in such a disease, and help ACLF patients in need, said John Tchelingerian, PhD, President and Chief Executive Officer of the Promethera Group. We are proud and excited to begin working towards the next milestone in the clinical development of HepaStem with the Phase 2b trial commencing and are looking forward to achieve the targets we set and bring HepaStem one step closer to an approved therapy.

In the previously concluded HEP101 trial, HepaStem has proven safe and tolerable in single or repeated injections in a total of 24 patients with Acute-on-Chronic Liver Failure (ACLF) or Acute Decompensation (AD) at high risk of developing ACLF. With one or two repeated doses up to 1.2 million cells per kilogram of body weight, no adverse events related to HepaStem occurred in the three-months follow-up period and no clinically significant changes were shown in platelet count, fibrinogen levels, and coagulation factors following HepaStem infusion. In addition to the positive safety profile, the study had shown preliminary signs of efficacy with improvement in three indicators of liver disease severity; Model for End Stage Liver Disease score (MELD), Child-Pugh score and bilirubin levels, 28 days and three months after treatment initiation.

About HepaStem

HepaStem consists of liver derived stem cells that are obtained from ethically donated healthy human organs and expanded in GMP culture conditions. Updated clinical data from the ongoing phase 2a study (HEP101) in patients with Acute-on-Chronic Liver Failure (ACLF) or Acute Decompensation (AD) at high risk of developing ACLF have been presented in an oral presentation at the Annual Meeting of the American Association for Study of Liver Diseases (AASLD) on November 10, 2019, in Boston, by Prometheras principal investigator Prof. F. Nevens, KULeuven, Belgium. The data set confirmed earlier findings presented at The International Liver Congress - ILC 2019 in April. A first clinical trial in NASH was initiated H1 2019.

About Promethera Biosciences SA (Promethera Group)

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert, Belgium, Durham, NC, USA, Tokyo, Japan and Basel, Switzerland.

Promethera, HepaStem, H2stem, are all registered trademarks of the PROMETHERA group.

Contact Information:

Read more from the original source:
Promethera Announces Initiation of Phase 2b DHELIVER Study of HepaStem in Patients with Acute-on-Chronic Liver Failure (ACLF) - Business Wire

Avacta and Daewoong Pharmaceutical Form Immunotherapy Focused Joint Venture – Technology Networks

Avacta, the developer of Affimer biotherapeutics and reagents, and Daewoong Pharmaceutical, a Korean pharmaceutical company, have announced an agreement to establish a joint venture in South Korea, and to enter a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies incorporating Affimer proteins to enhance the immune-modulatory effects.

Mesenchymal stem cells (MSCs) are promising agents for the treatment of autoimmune and inflammatory diseases. The joint venture will develop a new class of MSCs that are primed to produce Affimer proteins, which are designed to enhance the immune-modulatory effect when administered to patients, by reducing inflammatory or autoimmune responses.

Daewoong will provide the joint venture with access to its proprietary technology for generating allogeneic MSCs from a single donor to treat a large number of patients. This proprietary technology facilitates developing cell therapies as off-the-shelf products.

Avacta will develop Affimer proteins against several undisclosed targets which will be transferred to the joint venture to be incorporated into MSCs. The resulting engineered MSCs are aimed to have broad-ranging therapeutic utility, depending on the Affimer proteins intended therapeutic purposes.

Avactas research and development costs will be fully covered by the joint venture and Avacta retains the rights to commercialize the Affimer proteins outside of the field of cell therapies. Avactas shareholding in the joint venture is 45% with Daewoong holding 55%, and the joint venture will be operationally managed by Seng-ho Jeon, CEO of Daewoong, with a Board composed of representatives of both Avacta (Alastair Smith, CEO and Matthew Vincent, VP Business Development and Strategy) and Daewoong.

Affimer proteins have the potential to selectively modulate signaling pathways in inflammatory diseases in order to reduce the aberrant immune response occurring in those tissues, as well as positively impacting tissue regenerative pathways meant to repair and restore normal function to the affected tissues. We look forward to working closely with the Daewoong team to advance these promising therapeutics and get them to the patients who need them. said Dr Alastair Smith, CEO of Avacta.

View post:
Avacta and Daewoong Pharmaceutical Form Immunotherapy Focused Joint Venture - Technology Networks

Global Stem Cell Therapy Market Size is anticipated to grow at a strong CAGR by 2025 – Technology Magazine

A concise report on Stem Cell Therapy market Added by Market Study Report, LLC, features latest statistics and facts about market size, profit estimation and geographical spectrum of this industry. Furthermore, the report elucidates major challenges as well as the latest expansion strategies implemented by leading players of the Stem Cell Therapy market.

Request a sample Report of Stem Cell Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2422751?utm_source=technologymagazine.org&utm_medium=sp

The recent document on the Stem Cell Therapy market involves breakdown of this industry as well as division of this vertical. As per the report, the Stem Cell Therapy market is subjected to grow and gain returns over the predicted time period with an outstanding growth rate y-o-y over the predicted period.

As per the study, information regarding valuable estimation of the Stem Cell Therapy market related to the sales capacity, profit projections, market size and other crucial parameters are present. Data regarding the industry segmentation along with the driving forces impacting the enumeration scale of this industry is included in the report.

Enumerating the Stem Cell Therapy market with regards to the geographical landscape

Ask for Discount on Stem Cell Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2422751?utm_source=technologymagazine.org&utm_medium=sp

An outline of important points of the Stem Cell Therapy market report

is included in the report.

. The study consists of data about the products and provides data related to the market share of these products.

. It also speaks about the market share registered by the application segments.

The Stem Cell Therapy market report states that the industry is presumed to account a significant revenue over the predicted time period. It consists of data concerning the market dynamics such as challenges, growth opportunities along with the issues affecting the business domain.

For More Details On this Report:https://www.marketstudyreport.com/reports/global-stem-cell-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2025

Some of the Major Highlights of TOC covers:

Executive Summary

Manufacturing Cost Structure Analysis

Development and Manufacturing Plants Analysis of Stem Cell Therapy

Key Figures of Major Manufacturers

Related Reports:

1. Global Pediatrics Hearing Aids Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025This report includes the assessment of Pediatrics Hearing Aids market size for value and volume. Both top-down and bottom-up approaches have been used to estimate and validate the Pediatrics Hearing Aids market, to estimate the size of various other dependent submarkets in the overall market.Read More: https://www.marketstudyreport.com/reports/global-pediatrics-hearing-aids-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

2. Global Coronary Stents Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Coronary Stents Market Report covers a valuable source of perceptive information for business strategists. Coronary Stents Industry provides the overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elegant description of the value chain and its distributor analysis.Read More: https://www.marketstudyreport.com/reports/global-coronary-stents-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Related Reports: https://www.marketwatch.com/press-release/neuroendoscopy-market-share-detailed-analysis-of-current-industry-figures-with-forecasts-growth-by-2025-2020-01-07

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See the original post:
Global Stem Cell Therapy Market Size is anticipated to grow at a strong CAGR by 2025 - Technology Magazine

Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 – ReportsPioneer

Maximize Market Research published a Stem Cell Therapy Market report by keeping key players, end user, investors and all key stakeholders into consideration.

Stem Cell Therapy Market is expected to reach 202.77 billion by 2026 from XX billion in 2018 at CAGR of XX %.

The report will give in-depth analysis of market dynamics with competitive landscape, which will help user to understand their position in the market and ultimately will help to plan the strategies and implement the same as well.

The report includes PESTLE, Porters Five Forces, qualitative, and quantitative analysis that will help players to understand the market dynamics with current market size by region from supply side as well as from demand side. The regional analysis section unveils hidden market opportunities available in different regions and countries and in different segments.

Get PDF template of Stem Cell Therapy market report @ https://www.maximizemarketresearch.com/request-sample/522

Primary and secondary data collection methods are used to collect the data from reliable sources across the globe that include key players, end users, suppliers, members of associations across the countries and end user industries.Advanced research techniques and tools are used to prepare the report that make this report accurate and up-to-date with latest industry trends.

The global Stem Cell Therapy market is segmented by Treatment,Application,End Users and Geography. Each segment of the global Stem Cell Therapy market is thoroughly examined as per crucial factors such as market share, revenue, production, and CAGR. The report provides the statistical analysis where in market leaders followers and new entrants revenue, production, CAGR, M&A activities are presented in simple and format. Other aspects of the global Stem Cell Therapy market, including value chain, manufacturing cost, prices, gross margin, drivers, restraints, opportunities, Threats, and trends are also deeply analyzed.

Chiesi Farmaceutici S.P.A Are: Gamida Cell ReNeuron Group, plc Osiris Therapeutics, Inc. Stem Cells, Inc. Vericel Corporation. Mesoblast, Ltd.

DO INQUIRY BEFORE PURCHASING REPORT HERE @ https://www.maximizemarketresearch.com/inquiry-before-buying/522

Scope of the Global Stem Cell Therapy Market

Stem Cell Therapy Market, By Treatments:

Allogeneic Stem Cell TherapyAutologous Stem Cell Therapy

Stem Cell Therapy Market, By End Users:

HospitalsAmbulatory Surgical Centers

Stem Cell Therapy Market, By Application:

OncologyCentral Nervous System DiseasesEye DiseasesMusculoskeletal DiseasesWound & InjuriesMetabolic DisordersCardiovascular DisordersImmune System DisordersStem Cell Therapy Market, By Geography:

North AmericaEuropeAsia PacificMiddle East & AfricaLatin America

Market Forecasting

Besides short-term and long-term estimations related to the global Stem Cell Therapy market, repots has covered the demand, consumption, growth, and future course of market by region in the industry.

Customized Research

The report can be customized as per specific requirements of the clients.

Browse Full Report with Facts and Figures of Stem Cell Therapy Market Report @ https://www.maximizemarketresearch.com/market-report/stem-cell-therapy-market/522/

Table of Contents

Global Stem Cell Therapy Market

1. Preface1.1. Report Scope and Market Segmentation1.2. Research Highlights1.3. Research Objectives

2. Assumptions and Research Methodology2.1. Report Assumptions2.2. Abbreviations2.3. Research Methodology2.3.1. Secondary Research2.3.1.1. Secondary data2.3.1.2. Secondary Sources2.3.2. Primary Research2.3.2.1. Data from Primary Sources2.3.2.2. Breakdown of Primary Sources

Table of Contents Continuous..

Study Coverage: This is the first section of the report that includes highlights of market segmentation, years covered, study objectives, major manufactures of the global Stem Cell Therapy market, and product scope.

About Us:

Maximize Market Research provides syndicate as well as custom made business and market research on 6,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact Info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Continue reading here:
Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 - ReportsPioneer

Global Gene Therapy Market is Expected to Reach US$ 5,609.9 Million by 2027, Growing at an Estimated CAGR of 8.2% Over the Forecast Period as…

PUNE, India, Jan. 8, 2020 /PRNewswire/ -- In terms of revenue, global gene therapy market was valued at US$ 919.6 million in 2018 and is anticipated to reach US$ 5,609.9 million by 2027, growing at a CAGR of 8.2% over the forecast period. Market participants are adopting partnerships or acquisition as their strategy to strengthen their foothold. For instance, Pfizer Inc. acquired Medivation, Inc. and Bamboo Therapeutics, Inc. to develop a focused product for the treatment of patients with rare diseases related to neuromuscular and central nervous system. Companies are building relationships with community and patients to understand the disease and design therapies accordingly.

Request for Sample Copy of This Report@ https://www.absolutemarketsinsights.com/request_sample.php?id=308

Lethal diseases like cancer can be treated using gene therapy by inserting the antisense strands to revert the effect of the oncogenes using bio engineered vectors. Recently, scientists developed bionic chip to transfer DNA to cells using electroporation technique. During the forecast period, nanoparticles will play an important role in gene delivery systems to increase the efficiency of transfection of the non-viral carriers, thereby, fuelling the gene therapy market.

Due to drastic shift in treatment patterns, gene therapy treatment is considered one of the reliable cures for lethal diseases. The vectors or the DNA carriers are safer and have improved in terms of carrying genes without rejection which help the companies to attract venture capitalists to invest more in gene therapy market. Most of the research companies are focusing on development of gene carriers for the successful gene delivery. One of the prominent used vectors among the gene vehicle family is adeno associated virus. Cancer and Sensory disorders are the major area of concern that need to be fixed and hence drug development related to these disease is driving the gene therapy market.

Enquiry Before Buying @ https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=308

The detailed research study provides qualitative and quantitative analysis of gene therapy market. The market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

Key Findings of the Report:

Request for Customization@ https://www.absolutemarketsinsights.com/request_for_customization.php?id=308

Gene Therapy Market

By Geography

For More Information Visit@ https://www.absolutemarketsinsights.com/reports/Gene-Therapy-Market-2019-2027-308

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization.

From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:Company:Absolute Markets InsightsEmail id:sales@absolutemarketsinsights.comPhone:+91-740-024-2424Contact Name:Shreyas TannaThe Work Lab, Model Colony, Shivajinagar, Pune, MH, 411016Website:https://www.absolutemarketsinsights.com/

SOURCE Absolute Markets Insights

The rest is here:
Global Gene Therapy Market is Expected to Reach US$ 5,609.9 Million by 2027, Growing at an Estimated CAGR of 8.2% Over the Forecast Period as...

CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis – Associated Press

MENLO PARK, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases and extend healthy lifespan, today announced the discovery of a series of novel mitochondrial peptide analogs with potent in vitro activity as selective inhibitors of C-X-C Chemokine Receptor Type 4 (CXCR4) and with preliminary in vivo efficacy in a mouse model of melanoma, including substantial reduction in tumor growth as compared to control animals. CXCR4 is a key regulatory receptor involved in tumor growth, invasion, angiogenesis, metastasis, and resistance to therapy.

This new discovery offers the potential to develop novel therapeutics for difficult-to-treat cancers, based on peptides encoded in the mitochondrial genome, said Ken Cundy, Ph.D., CohBars Chief Scientific Officer. Inhibition of this key regulatory pathway is potentially applicable to a wide range of cancers, as well as orphan indications where CXCR4 signaling is dysregulated.

Novel peptide analogs of a mitochondrially encoded peptide (MBT5) demonstrated potent and selective inhibition of human CXCR4 receptor in cell-based assays, with IC50 values in the low nanomolar concentration range. In a difficult-to-treat in vivo mouse model of melanoma, the B16F10 syngeneic tumor model, the combination of an analog of MBT5 administered subcutaneously with the chemotherapeutic temozolomide showed enhanced antitumor activity, reducing tumor growth after 11 days by 61% compared to control animals. The reduction in tumor growth produced by the combination exceeded the effect of either temozolomide used as a single agent, which reduced tumor growth by 38% compared to control, or the murine checkpoint inhibitor anti-PD-1 antibody, which had no effect on tumor growth in this model.

CohBar plans to further explore the efficacy of this new family of peptides in additional animal models with the goal of identifying a new clinical development MBT candidate.

These new data further expand our understanding of the broad regulatory influence exerted by mitochondria and the therapeutic potential of analogs of peptides encoded in mitochondrial DNA, said Steve Engle, CohBar CEO. We are just beginning to scratch the surface of this previously untapped field.

CXCR4 is overexpressed in more than 75% of cancers and high levels of the receptor are associated with poor survival prognosis. Inhibition of the CXCR4 receptor has been shown to mobilize immune cells, enhance the effects of chemotherapy and immunotherapy in various cancers, and reduce the development of metastatic tumors by blocking the ability of tumor cells to evade immune surveillance. CXCR4 also regulates the homing and retention of hematopoietic stem cells and malignant cells in the bone marrow.

Further details of these new studies will be available on the CohBar website at http://www.cohbar.com.

About CohBar

CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBars founders of a novel group of naturally occurring mitochondrial-derived peptides within the mitochondrial genome that regulate metabolism and cell death, and whose biological activity declines with age. To date, the company has discovered more than 100 mitochondrial-derived peptides. CohBars efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases, cancer, type 2 diabetes, and cardiovascular and neurodegenerative diseases. The companys lead compound, CB4211, is in the phase 1b stage of a phase 1a/1b clinical trial that includes an evaluation of biological activity relevant to NASH and obesity.

For additional company information, please visit http://www.cohbar.com.

Forward-Looking Statements

This news release contains forward-looking statements which are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as believe, may, will, estimate, continue, anticipate, intend, could, should, would, project, plan, expect, goal, seek, future, likely or the negative or plural of these words or similar expressions. Examples of such forward-looking statements including but not limited to statements regarding the ability of mitochondrial peptide analogs to reduce tumor growth in mice; anticipated outcomes of research and clinical trials for our mitochondria based therapeutic (MBT) candidates; expectations regarding the growth of MBTs as a significant future class of drug products; and statements regarding anticipated therapeutic properties and potential of our mitochondrial peptide analogs and MBTs. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: our ability to successfully advance drug discovery and development programs, including the delay or termination of ongoing clinical trials; our possible inability to mitigate the prevalence and/or persistence of the injection site reactions, receipt of unfavorable feedback from regulators regarding the safety or tolerability of CB4211 or the possibility of other developments affecting the viability of CB4211 as a clinical candidate or its commercial potential; results that are different from earlier data results including less favorable than and that may not support further clinical development; our ability to raise additional capital when necessary to continue our operations; our ability to recruit and retain key management and scientific personnel; and our ability to establish and maintain partnerships with corporate and industry partners. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at http://www.sec.gov or http://www.sedar.com.

You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.

Investor and Media Contact:Jordyn TaraziDirector of Investor RelationsCohBar, Inc.(650) 445-4441 Jordyn.tarazi@cohbar.com

Joyce AllaireLifeSci Advisors, LLC jallaire@lifesciadvisors.com

Continued here:
CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis - Associated Press

Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing – Yahoo…

ROCKVILLE, Md., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for liquid and solid tumors,today announced the appointment of Christopher Ballas, Ph.D., as Senior Vice President of Manufacturing. Dr. Ballas previously served in senior manufacturing roles at Rocket Pharmaceuticals and WuXi AppTec, with a focus on gene and cell-based therapies.

Our need for quality vector and cell production is growing as we advance our liquid and solid tumor CAR-T programs into the clinic in the United States. We intend to assume full control of our key manufacturing processes, said Larry (Lei) Xiao, Ph.D., ICTs Founder and Chief Executive Officer. Chris is a valued addition to the ICT management team, as he will lead our manufacturing efforts and the expansion of our related infrastructure, Dr. Xiao added.

Dr. Ballas brings more than 20 years experience of working on cell and gene therapies. Most recently, he served as Vice President of Manufacturing for Rocket Pharmaceuticals, a leading publicly traded U.S. gene therapy company. Previously, he served as Senior Director of Process Development and Commercialization for WuXi AppTec, where he was responsible for manufacturing operations and program management for gene therapy clients. Dr. Ballas oversaw key programs including CAR-T, TIL, and classic CD34+ stem cell gene therapy.

Prior to WuXi AppTec, Dr. Ballas ran autologous cell therapy clinical trials for Cook Medical. Dr. Ballas also held several roles at the Indiana University School of Medicine, where he developed the initial, scalable, clinical production capabilities for lentiviral vectors at the IU Vector Production Facility. As a faculty member, Dr. Ballas developed his own research programs targeting stem cells for gene therapy, which resulted in the collaborative development of an ultra-high throughput microinjection device with colleagues at the University of California Riverside (US9885059). In the past, Dr. Ballas served as an expert consultant to numerous companies on gene therapy and the production and use of viral vectors for gene therapies with contributions to Chemistry, Manufacturing and Control (CMC), regulatory filings, and regulatory meetings.

Dr. Ballas has a Ph.D. in Cellular and Molecular Pathology from the Vanderbilt University School of Medicine and was a Childrens Brittle Bone Foundation fellow during his post-doctoral fellowship at Case Western Reserve University School of Medicine.

Dr. Ballas said, I have a passion for solving the practical challenges associated with producing and using viral vectors to deliver genes and create differentiated therapies. ICTs CAR-T platform is unique and compelling, and I look forward to leveraging my experience to optimize and expand our manufacturing capability to produce world-class products with the potential to transform cancer immunotherapy.

About Innovative Cellular TherapeuticsInnovative Cellular Therapeutics (ICT) is a clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of liquid and solid tumors. ICT has achieved promising preclinical and clinical results in late-stage leukemia and lymphoma with its next generation CAR-T constructs. ICTs lead candidate in the United States, ICTCAR014, is a next generation CD19-targeting ArmoredCARTM T cell therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application clearance and is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. In solid tumor, ICT has compelling human data from IRB-approved proof-of-concept trials in China demonstrating the viability of its proprietary CoupledCARTM technology platform. For more information, please visitwww.ictbio.com.

Read more here:
Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing - Yahoo...

Kevin Nash on How His Health Is After Knee Replacement & Stem Cell Therapy, Why He Retired – LordsofPain.net

WWE Hall of Famer Kevin Nash took to Twitter this week with several tweets on his health.

Nash made a tweet on Monday and apparently responded to a recent report or quote on his retirement status. The former WWE Champion said hes in the best physical shape as far as function hes been in since 1986.

How after wrestling once in 2 years as a favor is it news Im retired? I had a knee replacement and stem cell therapy to heal my wounds. Now Im in the best physical shape as far as function than Ive been since 1986 when I destroyed my right knee. I worked 29 years on one leg, Nash tweeted.

Nash made another tweet on Tuesday and included photos to show off the impressive physical shape that he is in at 60 years old. He commented on the knee replacement and two years of rehab & training hes went through.

The reason I retired was I was deformed and basically crippled, Nash revealed. This knee replacement and 2 years of rehab and training has been brutal. Just get my hips to realign was incredibly painful. To the haters fuck off To those that have championed my recovery I send my thanks and love.

Nash is set to become a two-time WWE Hall of Famer during WrestleMania 36 weekend in Tampa later this year as the nWo is inducted as a group (Nash, Hulk Hogan, Scott Hall, Sean Waltman).

You can see Nashs full tweets with photos below:

Follow Marc on Twitter at @this_is_marc. Send any news, tips or corrections to us by clicking here.

See the original post:
Kevin Nash on How His Health Is After Knee Replacement & Stem Cell Therapy, Why He Retired - LordsofPain.net

Stem Cell Alopecia Treatment Market 2019 Globally Expected to Drive Growth through 2024 – ReportsPioneer

With a multi-correctional approach, MRInsights.biz presents an extensive analysis of the historical, current and future outlook of the global Stem Cell Alopecia Treatment market along with the factors responsible for such a growth. The study author has served a complete outline of the market in a crystal clear format through which only an unskilled individual but also a professional can easily hypothesize the market easily. Our highly dedicated professionals have included critical and accurate insights related to the industry.

The report enhances the readers experience by giving a basic overview of the market and its classification. We have considered 2019 as the base year, 2024 as the estimated year, and 2019-2024 as the stipulated timeframe. The report proposes the segmental study of the global Stem Cell Alopecia Treatment market where it divides the periphery of the industry into segments such as product type, applications of the market, regional market spaces, and more.

DOWNLOAD FREE SAMPLE REPORT: https://www.mrinsights.biz/report-detail/185248/request-sample

Stem Cell Alopecia Treatment Market Competitive Rivalry:

The report highlights company profiles of the leading player combined with the investment forecast, the recent technology trends, and future forecasts. In addition, the section covers key financial knowledge, current developments, strategies employed by the major players, and SWOT outline. Along with the rise in innovation, mergers and acquisition activities in the industry, the market opposition is continuously developing greater.

The leading manufacturers and suppliers of the in-market include: Company 1, Company 2, Company 3, Company 4, Company 5, .,

Major regions that play a vital role in Stem Cell Alopecia Treatment market are: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

The market can be segmented into product types as: Alopecia Areata, Alopecia Totalis, Alopecia Universalis

The market can be segmented into applications as: Hospitals, Clinic, Others

The report further highlights the factors hampering the development, leading companies, supply-demand chain, futuristic facts, economic strategies, government policies, and topological statistics. It has carefully discussed client-specific details such as enterprise gross margin, present industrial policies, market statistics, import-export details, and government regulations. Some of the key focuses of Stem Cell Alopecia Treatment market covered in the report includes key trends such as technology advancement, globalization, capacity in developed markets, market bifurcation, product production, and regulation & environmental concerns.

ACCESS FULL REPORT: https://www.mrinsights.biz/report/global-stem-cell-alopecia-treatment-market-2019-by-185248.html

Research Study Offers A Detail Analysis of This Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Read the rest here:
Stem Cell Alopecia Treatment Market 2019 Globally Expected to Drive Growth through 2024 - ReportsPioneer